3,4-Methylenedioxy-N-ethylamphetamine
3,4-Methylenedioxy-N-ethylamphetamine
3,4-Methylenedioxy-N-ethylamphetamine (MDEA) is a synthetic entactogen of the amphetamine class. It is chemically related to MDMA and MDA, and is known for its psychoactive effects. MDEA is commonly referred to as "Eve" in the context of recreational use.
Chemical Structure and Properties
MDEA is a member of the phenethylamine and amphetamine chemical classes. Its chemical structure consists of a methylenedioxy ring attached to the phenyl group, with an ethyl group attached to the nitrogen atom of the ethylamine chain. This structure is similar to that of MDMA, with the primary difference being the ethyl group in place of the methyl group.
Pharmacology
MDEA acts primarily as a serotonin-norepinephrine-dopamine releasing agent (SNDRA). It increases the levels of these neurotransmitters in the brain, leading to its psychoactive effects. The entactogenic effects of MDEA are attributed to its action on the serotonin system, similar to other drugs in the MDxx family.
Effects
The effects of MDEA are similar to those of MDMA, though generally considered to be less intense. Users report feelings of euphoria, increased sociability, and enhanced sensory perception. The duration of effects typically lasts 3 to 6 hours, with a peak occurring around 1 to 2 hours after ingestion.
Synthesis
MDEA can be synthesized from safrole, a precursor also used in the synthesis of MDMA and MDA. The synthesis involves several chemical reactions, including the formation of the methylenedioxy ring and the attachment of the ethylamine chain.
Legal Status
MDEA is classified as a Schedule I controlled substance in many countries, including the United States, under the Controlled Substances Act. This classification indicates that it is considered to have a high potential for abuse and no accepted medical use.
Related Compounds
- MDMA (3,4-Methylenedioxy-N-methylamphetamine)
- MDA (3,4-Methylenedioxyamphetamine)
- MBDB (3,4-Methylenedioxy-N-methylbutanamine)
Related Pages
Gallery
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD